*****CONTINUATION LOOKS ON THE CARDS TODAY, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOD VOLUME . CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING.
***********NEWS FLOW*********
The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that...
******CONTINUATION LOOKS ON THE CARDS TOMORROW, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOV VOLUME. CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING.
***********NEWS FLOW*********
The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that...
Shares of Iovance Biotherapeutics, a clinical-stage biotechnology company, are on the move after a clinical program update. Investors who are pleased to see the company's oncology candidates getting closer to the finish line pushed the stock 20.4% higher on Wednesday.
I find stocks with this certain structure usually continue to go up. That is, an uptrend where 80%-95% of the days are green and keep their strength when it matters, like the last two weeks. Despite the major move from 8.50 to 18.00 it has held current price and its resilience is shown by staying above the 10dma when it comes to closing prices. Friday was good...
If the market decides to make this stock go uptrend again then a next key level might be $8.11.
If not, or for speculators expecting a bearish trend, another key level might be $7.60.
Manage your risk exposure correctly :)
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
IOVA
